cost-effectiveness

News

New drugs 'benefit patients, but maybe not populations'

The money spent by the NHS on newly approved therapies recommended by NICE might have been better spent elsewhere, according to a new study.

News

PHTI backs virtual therapies for musculoskeletal disorders

A new report from the Peterson Health Technology Institute has concluded that many digital therapies for musculoskeletal (MSK) conditions like low back pain can deliver cl

News

ICER raps conduct of Lykos’ psychedelic trial for PTSD

The Institute for Clinical and Economic Review (ICER) typically focuses on the cost-effectiveness of new therapies, but in an unusual move has sharply criticised the desig

News

Leqembi still too pricey, says ICER in updated review

Side effects create 'uncertainties' as to whether lecanemab's benefits exceed its risks.

News

x-ray image of human head with brain and electric pulses

ICER says lecanemab data in Alzheimer's "inconclusive"

One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<

News